Fesoterodine MedChemExpress (MCE)

Product Name	Fesoterodine ((S)-2-hydroxy-2-phenylacetic acid)
Synonyms	FESOTERODINE L-MANDELATE;Fesoterodine L-mandelate;Fesoterodine ((S)-2-hydroxy-2-phenylacetic acid);2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-hydroxy-methylphenyl isobutyrate mandelate
CAS	1206695-46-6
EINECS
Chemical Formula	C34H45NO6
Molecular Weight	563.7242
inchi
Package	10 mM * 1 mL;5 mg;10 mg;50 mg;100 mg;500 mg
Price	Email to quote
Descriptions	Fesoterodine L-mandelate Fesoterodine L-mandelate MedChemExpress (MCE) HY-70053A 1206695-46-6 99.00% 4°C, sealed storage, away from moisture In solvent : -80°C, 6 months Descriptions Fesoterodine L-mandelate Fesoterodine L-mandelate MedChemExpress (MCE) HY-70053A 1206695-46-6 99.00% 4°C, sealed storage, away from moisture In solvent : -80°C, 6 months -20°C, 1 month (sealed storage, away from moisture) Room temperature in continental US may vary elsewhere. Fesoterodine L-mandelate is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pKi values of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine L-mandelate is used for the overactive bladder (OAB). Fesoterodine L-mandelate decreases micturition frequency, urgency severity and urgency incontinence episodes and increases the volume voided with each micturition[1]. After oral administration, Fesoterodine L-mandelate is rapidly and extensively hydrolysed in plasma by nonspecific esterases to Desfesoterodine (5-hydroxymethyl tolterodine SPM 7605 HY-76569 an active metabolite of Fesoterodine)[3][4]. Fesoterodine L-mandelate (0.01-1 mg/kg IV) reduces the micturition pressure and increases bladder capacity and ICIs (intercontraction intervas) at the lowest dose tested of 0.01 mg/kg[3]. mAChR1 mAChR3 mAChR4 mAChR5 \| \| \| \| \| \| \| \| \| \| [1]. Ellsworth P, et al. Fesoterodine for the treatment of urinary incontinence and overactive bladder. Ther Clin Risk Manag. 2009 5:869-76. Epub 2009 Nov 18. [Content Brief] [2]. Didem Yilmaz-Oral, et al. The Beneficial Effect of Fesoterodine, a Competitive Muscarinic Receptor Antagonist on Erectile Dysfunction in Streptozotocin-induced Diabetic Rats [Content Brief] [3]. Peter Ney, et al. Pharmacological Characterization of a Novel Investigational Antimuscarinic Drug, Fesoterodine, in Vitro and in Vivo. BJU Int. 2008 Apr 101(8):1036-42. [Content Brief] [4]. Martin C Michel, et al. Fesoterodine: A Novel Muscarinic Receptor Antagonist for the Treatment of Overactive Bladder Syndrome. Expert Opin Pharmacother. 2008 Jul 9(10):1787-96. [Content Brief]
Last Update	2025-04-01 14:45:47

MedChemExpress (MCE) also provides

Thalidomide-4-O-C2-NH2

Category: Signaling Pathways
CAS: 2341840-99-9
Last Update: 2025-04-01 14:45:47

PPARα-MO-1

Category: Signaling Pathways
CAS: 810677-36-2
Last Update: 2025-04-01 14:45:47

Netupitant N-oxide

Category: Signaling Pathways
CAS: 910808-11-6
Last Update: 2025-04-01 14:45:47

MK-0812

Category: Signaling Pathways
CAS: 624733-88-6
Last Update: 2025-04-01 14:45:47

TS-011

Category: Signaling Pathways
CAS: 339071-18-0
Last Update: 2025-04-01 14:45:47

SCH 530348 sulfate

Category: Signaling Pathways
CAS: 705260-08-8
Last Update: 2025-04-01 14:45:47

BAG 956

Category: Signaling Pathways
CAS: 853910-02-8
Last Update: 2025-04-01 14:45:47

YM758

Category: Signaling Pathways
CAS: 312752-85-5
Last Update: 2025-04-01 14:45:47


Supplier Name	MedChemExpress (MCE)
Contact	sales
Tel	609-228-6898
Mobile	609-228-6898
QQ
Email	sales@medchemexpress.com; tech@medchemexpress.com
Website	https://www.medchemexpress.com/
Wechat

Request for quotation

Supplier Contact